Search Orphan Drug Designations and Approvals
-
| Generic Name: | (R)-2-((1-(2-(4-methoxy-3-(2-morpholinoethoxy) phenyl)-5-methylthiazol-4-yl)ethyl)thio)pyrimidine-4,6-diamine |
|---|---|
| Date Designated: | 01/07/2021 |
| Orphan Designation: | Treatment of acute disseminated encephalomyelitis |
| Orphan Designation Status: | Designated |
| FDA Orphan Approval Status: | Not FDA Approved for Orphan Indication |
| Sponsor: |
Trethera Corporation 13547 Ventura Boulevard, Suite 363 Sherman Oaks, California 91423 United States The sponsor address listed is the last reported by the sponsor to OOPD. |
*Data for the Date Designation Withdrawn or Revoked field are shown for designations withdrawn or revoked after 08/12/2013.
-







